Development of nover antigen delivery system for tumor therapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15108
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Physical pharmacy
• Research Institution: The University of Tokushima
• Principal Investigator: ISHIDA Tatsuhiro 徳島大学, 大学院医歯薬学研究部(薬学系), 教授 (50325271)
• Co-Investigator(Kenkyū-buntansha): 清水 太郎 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (30749388)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: ワクチン / アジュバント / ナノキャリア

Outline of Final Research Achievements

Antigen delivery to antigen presenting cells (APC) is important for development of cancer vaccine. We have found that second dose PEGylated liposomes were selectively taken up by splenic marginal zone B cell (MZ-B), when they were injected with certain interval. This suggests that if antigen is encapsulated into second dose PEGylated liposome, antigen could be delivered to MZ-B, resulting in enhanced anti-tumor immune responses. In this study, we confirmed that delivery of antigen encapsulated in second dose PEGylated liposomes to MZ-B can enhance antitumor immune responses against primary tumor or transplanted tumor.

Free Research Field

薬剤学